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ABSTRACT
The major breast cancer story of 2005 was trastuzu-
mab, a monoclonal antibody directed against the Her-
2 oncoprotein, and how it greatly improves outcomes
for women with HER2-positive early-stage breast
cancer. With early results showing that use of the drug
can prevent roughly one half of relapses, adjuvant
trastuzumab has been approved, funded, and accepted
as the standard of care in many Canadian jurisdic-
tions. In the present brief report, we summarize the
four major adjuvant trials, outline some key contro-
versies, and suggest steps to provide more-effective
and better-tolerated adjuvant systemic therapy for the
relevant patient subgroup.
KEY WORDS
Early-stage breast cancer, trastuzumab, adjuvant therapy,
docetaxel, paclitaxel, carboplatin, doxorubicin
1. INTRODUCTION
Improvements in breast cancer detection and treat-
ment have contributed to declining breast cancer–
specific mortality rates since the mid-1990s 1,2. Still,
outcomes of early-stage breast cancer remain subop-
timal: women experience relapses despite state-of-
the-art adjuvant chemotherapy and hormonal therapy,
and distant metastatic disease most commonly leads
to premature death.
In 2005, we witnessed a revolution in adjuvant
breast cancer therapy, with reports of major reduc-
tions in risk of recurrence with the use of a biologi-
cally targeted agent. In the present brief report, we
summarize the early results from four large-scale
adjuvant trastuzumab studies, attempt to place the
currently available treatment options in context, and
discuss how controversies will be addressed in up-
coming clinical trials. Ultimately, we hope that these
discussions will assist Canadian health care provid-
ers and their breast cancer patients in making the treat-
ment decisions that they now face on a daily basis.
2. DISCUSSION
2.1 The Her-2 Pathway
A growing understanding of breast cancer biology
has identified new targets for therapy. We now ap-
preciate that growth factor receptors can trigger intra-
cellular signalling cascades that modulate the cell
cycle and apoptosis, influencing the behaviour of
breast cancer cells. Amplification of the human epi-
dermal growth factor receptor–2 gene (HER2) leads
to an overabundance of the Her-2 protein on the cell
surface, enhances dimerization of Her-2 with itself
or with other members of the epidermal growth fac-
tor receptor (EGFR) family, and triggers intracellular
tyrosine kinase activity and signal transduction path-
ways. The ultimate result of this Her-2 driven signal-
ling is inhibition of apoptosis and promotion of cell
growth, division, angiogenesis, and metastasis.
The HER2 alteration occurs in 20% – 25% of
human breast tumours 3,4 and can be identified by
protein overexpression as assessed using immuno-
histochemistry (IHC) or by gene amplification as as-
sessed using fluorescence in-situ hybridization (FISH)
or chromogenic in-situ hybridization. Disease that is
HER2-positive is associated with negative clinical
prognostic factors such as high tumour grade, DNA
aneuploidy, a high cell proliferation rate, estrogen or
progesterone negativity (or both), and TP53 gene
mutation. Aberrations in a variety of other molecular
biomarkers of breast cancer invasiveness and metasta-
sis have also been seen 5–7. As a result, breast can-
cers with HER2 overexpression have a more
aggressive disease course and poorer overall prog-
nosis than are seen with HER2-negative breast
cancers.
2.2 Trastuzumab
Trastuzumab (Herceptin: Genentech, San Francisco,
CA, U.S.A.) is a humanized monoclonal antibody
directed against the extracellular portion of the Her-
2 protein. Trastuzumab acts by activating antibody-
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dependent cellular cytotoxicity, directly disrupting
receptor dimerization and downstream effector sig-
nalling, and internalizing and degrading the recep-
tor. In model systems, trastuzumab reduced cellular
proliferation, suppressed angiogenesis, and ultimately
caused cell cycle arrest 8.
Patients with advanced HER2-positive cancers
benefit from trastuzumab therapy delivered either as
a single agent or in combination with chemotherapy.
In metastatic breast cancer, an objective response to
first-line single-agent trastuzumab was seen in 26%
of patients 9; however, in patients who had received
prior chemotherapy, the response rate was substan-
tially lower (approximately 12% – 15%) 10,11. Out-
comes—including response rate, time to progression,
and overall survival—are improved when trastuzu-
mab is given concurrently with chemotherapy 12–14.
2.3 The Major Adjuvant Trastuzumab Trials
2.3.1 Study Designs and Efficacy Signals
Four large-scale, randomized phase III studies are
evaluating the role of trastuzumab in the adjuvant
setting. Figure 1 depicts the design of those studies.
Descriptions of the trial populations, efficacy signals,
and cardiac safety data have been reported for each
study (Tables I – III).
National Surgical Adjuvant Breast and Bowel
Project (NSABP) B31 Trial and North Central Cancer
Treatment Group (NCCTG) N9831 Trial:The NSABP B31
protocol (Figure 1) randomized 1736 axillary node–
positive, HER2-positive breast cancer patients to
4 cycles of standard doxorubicin and cyclophospha-
mide (AC) followed by 4 cycles of paclitaxel adminis-
tered every 3 weeks (AC–P), or the same chemotherapy
with weekly trastuzumab starting concurrently with
TABLE I Overview of the trial populations in early breast cancer
trastuzumab studies (stage I–IIIA, MO, invasive adenocarcinoma)
N0 N+ IHC FISH Randomized EF
T1a T1b T1c
NSABP B31 üüü Pre-chemo ³50%
NCCTG ü üüü Pre-chemo ³50%
BCIRG 006 üüü ü ü Pre-chemo ³50%
HERA ü üüüPost-chemo ³55%
N0 = node-negative disease; N+ = node-positive disease;  ICH =
immunohistochemistry; FISH = fluorescence in-situ hybridization;
EF = left ventricular ejection fraction required for study entry;
NSABP = National Surgical Adjuvant Breast and Bowel Project;
NCCTG = North Central Cancer Treatment Group; BCIRG = Breast
Cancer International Research Group; HERA = Herceptin Adjuvant
Trial.
FIGURE 1 Adjuvant trastuzumab study designs. AC = doxorubicin–cyclophosphamide; T = docetaxel; H = trastuzumab; AT = doxorubicin–
taxane; AUC = area under the curve; BCIRG = Breast Cancer International Research Group; CMF = cyclophosphamide–methotrexate–5-
fluorouracil; CT = chemotherapy; EC = epirubicin-cyclophosphamide; ET = epirubicin-taxane; FAC = fluorouracil–doxorubicin-
cyclophosphamide;  FEC = fluorouracil–epirubicin–cyclophosphamide; FISH = fluorescence in-situ hybridization; ICH = immunohistochemistry;
NCCTG = North Central Cancer Treatment Group; NSABP = National Surgical Adjuvant Breast and Bowel Project; HERA = Herceptin Adjuvant
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the paclitaxel (AC–PH). In a somewhat similar approach,
NCCTG N9831, a three-armed study, randomized 1615
patients to 4 cycles of AC chemotherapy followed by
weekly paclitaxel (×12 weeks) with or without weekly
trastuzumab (×1 year) and allowed for comparison of
concurrent (that is, with paclitaxel) versus sequential
(that is, after completion of all chemotherapy) trastu-
zumab therapy. The populations in the two studies
varied somewhat, with N9831 including patients with
high-risk node-negative disease.
Although accrual had not finished, similarities
in the designs of these two studies prompted the in-
vestigators to perform a non-protocol (but U.S. Food
and Drug Administration–approved) combined in-
terim analysis 15. With a combined median follow-
up of 2.0 years (2.4 years in NSABP B31 and 1.5 years
in NCCTG N9831), significant benefits were observed
in the patients receiving adjuvant trastuzumab. The
primary endpoint of disease-free survival (DFS) was
improved in the trastuzumab-containing arms [haz-
ard ratio (HR): 0.48; p = 3×10–12) of the trials, and
remained so in all subsets. Preliminary data also sug-
gested longer overall survival in trastuzumab-treated
patients (HR: 0.67; 2p = 0.015).
Breast Cancer International Research Group
(BCIRG) 006 Trial:For combination with trastuzumab,
the BCIRG 006 trial selected docetaxel-based chemo-
therapy. This choice was made because of
docetaxel’s clinical efficacy in advanced breast can-
cer and the suggestion of preclinical synergy with
docetaxel, carboplatin, and trastuzumab 13,16,17. The
protocol randomized 3222 women with HER2-am-
plified, node-positive or high-risk node-negative
operable breast cancer to one of three study arms
(Figure 1):
• Arm 1: 4 cycles of standard AC chemotherapy fol-
lowed by 4 cycles of docetaxel administered
every 3 weeks (AC–T)
• Arm 2: 4 cycles of standard  AC chemotherapy,
followed by 4 cycles of docetaxel with concur-
rent weekly trastuzumab; then trastuzumab every
3 weeks to complete 1 year of antibody therapy
(AC–TH)
• Arm 3: Docetaxel–carboplatin–trastuzumab for
6 cycles, followed by trastuzumab every 3 weeks
to complete 1 year of antibody administration
(TCH)
TABLE III Cardiac safety in early breast cancer trastuzumab studies
NSABP B31 a NCCTG N9831 b HERA BCIRG 006 c
AC ® PA C  ® PH AC ® PA C  ® PH AC ® P ® H Nil H (1 year) AC ® TA C  ® TH TCH
CHF [n (%)] 4 31 0 20 16 0 9 3 17 4
(0.8) (4.1) (0.3) (3.5) (2.5) (0) (0.5) (0.3) (1.7) (0.4)
Cardiac death (n) 10 1 1 1 10 000
a Cumulative rates 24.
b Cumulative rates 25.
c Raw rates.
NSABP = National Surgical Adjuvant Breast and Bowel Project; NCCTG = North Central Cancer Treatment Group; HERA = Herceptin Adjuvant
Trial; BCIRG = Breast Cancer International Research Group; AC = doxorubicin–cyclophosphamide; P = paclitaxel; H = trastuzumab; T = docetaxel;
TCH = docetaxel–carboplatin–trastuzumab; CHF = New York Heart Association class 3 and 4 congestive heart failure.
TABLE II Efficacy in early breast cancer trastuzumab studies
NSABP B31, BCIRG 006 HERA
NCCTG N9831a AC ® TH TCH
Regimen Concurrent Concurrent Sequential
Follow-up 2 Years 2 Years 1 Year
Evaluable patients (n) 3351 3222 3387
Hazard ratios
DFS 0.48 0.49 0.61 0.54
2p=3×10–12 p<0.0001 p=0.0002 p<0.0001
DDFS 0.47 NR NR 0.51
2p=8×10–10 p<0.0001
OS 0.67 NR NR 0.76
2p=0.015 p=0.26
a Combined analysis.
NSABP = National Surgical Adjuvant Breast and Bowel Project; NCCTG = North Central Cancer Treatment Group; BCIRG = Breast Cancer
International Research Group; HERA = Herceptin Adjuvant Trial; AC ® TH  = doxorubicin–cyclophosphamide/docetaxel–trastuzumab; TCH =
docetaxel–carboplatin–trastuzumab; DFS = disease-free survival; DDFS = distant DFS; OS = overall survival.JOY and MACKEY
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All patients had HER2-amplified disease (FISH+)
as assessed by a centralized laboratory (Table II). The
study population also included high-risk node-nega-
tive disease (even if the primary tumours were small).
The occurrence of 300 DFS events triggered a pro-
tocol-specified interim analysis of BCIRG 006. With a
median follow-up of 23 months, adding trastuzumab
to docetaxel-based chemotherapy improved the pri-
mary endpoint of DFS. The AC–TH regimen produced
a 51% reduction in risk of recurrence [95% confi-
dence interval (CI): 35% to 65%; p < 0.00001]. The
TCH regimen produced a 39% reduction in risk of re-
currence (95% CI: 21% to 53%; p = 0.0002).
The AC–TH regimen had a greater numerical ben-
efit, but the two experimental trastuzumab-contain-
ing arms were not statistically different in terms of
efficacy. Further follow-up will be required to ad-
dress the relative efficacies of the two trastuzumab-
containing regimens 18.
An intriguing protocol-specified molecular cor-
relative study found that, although all tumours had
HER2 amplification, one third also had amplifica-
tion of the topoisomerase IIa (TOP2A) gene. The Top-
2A protein is the main molecular target of
anthracycline therapy. Patients with co-amplification
of HER2 and TOP2A had a very high DFS when treated
with AC–TH; the patients without TOP2A amplifica-
tion did not seem to benefit from anthracyclines.
Those patients had very good outcomes with the non-
anthracycline TCH regimen 19.
Herceptin Adjuvant Trial (HERA):The HERA interna-
tional clinical trial is led by the Breast International
Group. More than 5000 HER2-positive patients were
randomized into one of three arms following comple-
tion of adjuvant or neoadjuvant chemotherapy. Patients
received either a standard approach (observation with
no further treatment) or trastuzumab administered
every 3 weeks. The patients receiving trastuzumab
were randomly assigned to either 1 or 2 years of
therapy. Efficacy results for the standard approach and
the 1-year trastuzumab therapy treatment arms have
been reported. With a median follow-up of only 1 year,
improvement in the primary endpoint of DFS was seen
in the patients who received trastuzumab (2-year DFS:
85.8% vs. 77.4%; HR: 0.54; 95% CI: 0.43 to 0.67; p <
0.0001) 20.
2.3.2 Cardiotoxicity with Adjuvant Trastuzumab
Trastuzumab is generally well tolerated, and imme-
diate reactions such as infusion-related hypersensi-
tivity are relatively rare. Trastuzumab-associated
cardiotoxicity, however, is a major safety concern 21.
Most commonly, it presents as an asymptomatic re-
duction in cardiac ejection fraction and, less fre-
quently, as overt congestive heart failure (CHF).
Type II chemotherapy–related cardiac dysfunction
(CRCD)—as trastuzumab-associated cardiotoxicity has
been recently named 22—does not occur in all indi-
viduals exposed to trastuzumab, does not appear to be
dose-related, and when present, is variable in its se-
verity. Type II CRCD has no identifiable cardiac ultra-
structural abnormalities such as those seen in patients
previously exposed to anthracyclines 23. Standard
medical management of trastuzumab-associated CHF
results in significant symptom improvement, with most
patients (approximately 80%) achieving improvement
in symptoms with treatment 24. It appears that a major
risk factor for the development of type II CRCD is prior
or concurrent anthracycline exposure.
The four reported adjuvant trastuzumab studies
produced substantially different cardiac safety sig-
nals (Table III). It is difficult to determine how much
of the variability in the rates of grade 3 and 4 CHF is
attributable to differences in the study populations
(Table I) and how much to the varying ways of iden-
tifying and coding cardiac events. Nonetheless, car-
diac signals are clearly evident.
The highest reported cardiotoxicity rates occurred
in the NSABP B31 and NCCTG N9831 trials, where AC is
followed by concurrent administration of paclitaxel
and trastuzumab (3.5% – 4.1% rate of grade 3 and 4
CHF) 15,25. Approximately 15% of patients did not
complete the planned 1-year duration of trastuzumab
because of asymptomatic declines in left ventricular
ejection fraction (LVEF). Although the “reversibility”
of this cardiotoxicity and its long-term outcomes will
require more follow-up, the reported experience is
that most patients with cardiotoxicity experience reso-
lution of symptoms after discontinuing trastuzumab
and starting medical therapy.
Elimination of the anthracyclines in the BCIRG 006
study markedly reduced the rates of CHF from 1.7%
on the AC–TH arm to 0.4% on the TCH arm. Although
average asymptomatic decreases in LVEF on AC–TH
appeared to persist after treatment, TCH appeared to
allow full recovery of mean LVEF to baseline after
completion of treatment.
By limiting enrolment to women with a post-che-
motherapy LVEF of 55% or more, and by giving tras-
tuzumab after completion of chemotherapy, the HERA
trial produced a very low CHF rate of 0.5%.
2.3.3 Selecting an “Optimal” Adjuvant Trastuzumab
Approach
Currently, breast cancer patients and their physicians
have a choice of several adjuvant trastuzumab ap-
proaches. Head-to-head comparisons of these treat-
ment approaches are not available. In particular, the
critical comparison of sequential (arm 2) versus con-
current (arm 3) trastuzumab in the N9813 study is
not yet sufficiently mature to determine the best ap-
proach (although early results suggest superiority for
concurrent administration 26). We are thus in the un-
satisfying position of making cross-trial comparisons,
which are fraught with the problems of varying trial
design (Figure 1), varying patient populations, and
variability in eligibility based on tumour size, axil-ADJUVANT TRASTUZUMAB
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lary node status, and HER2 assessment method
(Table I).
The benefits for concurrent administration of tras-
tuzumab with paclitaxel, as per the combined analysis,
include clear efficacy, a demonstrated survival advan-
tage, early integration of trastuzumab (which might
reduce very early relapses), and a relatively short
15-month duration of infusional therapy. Potential
downsides include the highest reported risks of grades 3
and 4 CHF (between 3.5% and 4.1%) and longer infu-
sion chair times. For methodology purists, concerns in-
clude the difficulties of interpreting a trial in which
patients are still being accrued at the time of analysis,
and the question of whether the trial-mandated cross-
over of control patients to adjuvant trastuzumab might
obscure long-term safety and efficacy signals.
The potential benefits for concurrent administra-
tion of trastuzumab with docetaxel include early inte-
gration of trastuzumab with potentially synergistic
chemotherapy (which, again, might reduce very early
relapses), the shortest 12-month duration of infusional
therapy with TCH, and less infusion chair time. Although
not directly comparable, the risk of cardiotoxicity with
the docetaxel-based regimens appears to be less than
that seen with paclitaxel, and the TCH regimen appears
to be the least cardiotoxic option among the various
regimens (Table III). Should further follow-up confirm
the predictive value of TOP2A gene amplification, co-
amplification of TOP2A may be a useful molecular
marker to rationally separate patients who require
anthracyclines (and thus make the higher cardiotoxicity
rates of AC–TH somewhat more acceptable) from pa-
tients who would be better treated with TCH.
The potential benefits of administering trastuzu-
mab after chemotherapy include a lower risk of grades 3
and 4 CHF (0.5% in the HERA study, where trial entry
required a post-chemotherapy LVEF of 55% or more,
and 2.5% in the second arm of N9831, where trastuzu-
mab was given to women who, after weekly paclitaxel,
had an LVEF of 50% or more). The duration of total
infusional therapy varies with the chosen chemotherapy
regimen in HERA, ranging from 15 months to 18 months.
The HERA approach allows considerable flexibility in
the selection of chemotherapy regimens, and the trial
allowed aggressive anthracycline–taxane and cyclo-
phosphamide–methotrexate–fluorouracil regimens. The
possible downsides of this sequential approach include
the theoretic risk of early relapse before trastuzumab is
begun and the potential loss of synergistic chemo-
therapy–trastuzumab interactions. Fortunately, some of
these issues will be clarified by a more mature com-
parison of the N9831 study arms 2 and 3.
3. FUTURE DIRECTIONS
Adjuvant therapy for HER2-driven breast cancer con-
tinues to evolve. Although DFS is dramatically im-
proved in all reported studies, more time is needed to
definitively address effects on overall survival. Simi-
larly, only time will tell whether cardiotoxicity is a
transient and reversible complication of anthracycline
and trastuzumab exposure, or whether irreversible
cardiac damage will require long-term CHF therapy.
The optimal trastuzumab timing (with or after
chemotherapy) is unclear, and the optimal duration of
trastuzumab is also unknown. The N9831 study should
address the former question, but the most appropriate
duration of therapy will be answered, in part, by the
comparison of the 1-year and 2-year trastuzumab arms
in  HERA. In the meantime, a small study (n = 231
HER2-amplified patients) performed by Finnish in-
vestigators suggested that 9 weeks of trastuzumab
given concurrently with 3 cycles of docetaxel reduced
risk of recurrence by approximately 50% 27. That study
will undoubtedly spur trials of short-duration versus
standard 1-year adjuvant trastuzumab. Whether adju-
vant trastuzumab would benefit a woman in the ab-
sence of chemotherapy is unknown: proposed studies
will explore whether postmenopausal women with
estrogen receptor–positive, HER2-positive breast can-
cer treated with aromatase inhibitors alone benefit
from the addition of trastuzumab.
Most interesting, however, is how prognosis in
HER2-driven breast cancer might be further improved.
Preclinical and correlative studies are attempting to
identify mechanisms of trastuzumab resistance. Stud-
ies are in design to explore the relative merits of tras-
tuzumab and the dual EGFR/Her-2 tyrosine kinase
inhibitor, lapatinib, in early breast cancer. However,
an increasing body of preclinical and clinical evidence
shows that HER2 amplification drives pro-angiogenic
signals mediated, in part, by vascular endothelial
growth factor 28. Thus, to further improve the outlook
for patients with HER2-driven breast cancers, a strong
rationale exists to pursue studies of combination anti-
HER2 and anti-angiogenic therapy.
Trastuzumab represents the first major success
of rationally-designed breast cancer therapy, but the
story of HER2-targeted breast cancer therapy is by
no means over. We expect that the best is yet to come.
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